Biopharma | November 14, 2025
Transition Bio and Voyager Therapeutics forge strategic collaboration to target ALS, FTD
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The partnership aims to develop novel, selective small molecules targeting TDP-43 pathology
The new company aims to transform cutting-edge, highly scalable technologies into innovative drug discovery platforms
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
Phase 3 program for NDV-01 in non-muscle invasive bladder cancer expected to begin in the first half of 2026
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
SkinMedica redefines luxury skincare with reimagined packaging and new HA5 hydra collagen water burst moisturizer
Subscribe To Our Newsletter & Stay Updated
